Agilent Technologies reported Q3 2026 total revenue of $1.88 billion, up 8.1% year-over-year. Europe contributed $504 million (26.8%), missing analyst expectations by 3.24%, while Asia Pacific delivered $613 million (32.6%), beating estimates by 3.15%. The company holds a Zacks Rank #3 (Hold) rating, with stock gaining 11.2% over the past month versus the S&P 500's 3.9% increase.

The global laboratory informatics market is projected to grow at a CAGR of 5.06% from 2025 to 2035, driven by increased data processing demands, regulatory compliance requirements, and adoption of cloud-native solutions and AI-driven analytics. North America leads with 42.55% market share, while Asia-Pacific is the fastest-growing region. Services and LIMS products dominate, with cloud delivery and electronic lab notebooks showing the strongest growth rates.

The global gRNA (guide RNA) market is projected to grow from USD 518 million in 2024 to USD 2,950 million by 2034, representing a 19% CAGR. Growth is driven by increasing cancer research, infectious disease prevalence, technological innovation, and expanding applications in genome editing, functional genomics, diagnostics, cell & gene therapy, and agricultural biotechnology. Key market players include Thermo Fisher Scientific, Agilent Technologies, Merck KGaA, and others. Strategic partnerships and rising adoption of CRISPR technology in agriculture are major growth catalysts.

Artificial intelligence is fundamentally restructuring bioinformatics, compressing drug discovery timelines and attracting billions in venture capital. AI tools like AlphaFold and generative biology platforms are delivering measurable ROI, with companies achieving 99% cost reductions in drug discovery. North America leads adoption, supported by federal programs and substantial R&D investments from established life sciences players.

The global mass spectrometry market is valued at $6.68 billion in 2025 and is projected to reach $14.09 billion by 2035, growing at a CAGR of 7.74%. Growth is driven by pharmaceutical manufacturing, omics research, clinical diagnostics, and precision medicine adoption. North America leads the market while Asia Pacific records the fastest growth at 9.12% CAGR.

The global cancer biomarkers market is valued at USD 28.25 billion in 2026 and is projected to reach USD 54.48 billion by 2032, expanding at an 11.6% CAGR. Growth is driven by rising cancer incidence, technological advances, adoption of precision medicine, and liquid biopsy techniques. Omics technologies and breast cancer diagnostics lead segment growth, while Asia-Pacific emerges as the fastest-growing region. Key players include Roche, Thermo Fisher, Illumina, and Agilent Technologies.

The global oligonucleotide contract development and manufacturing organization (CDMO) market is experiencing strong growth driven by expanding RNA-targeted medicine pipelines, increased outsourcing of complex synthesis and manufacturing, and rising demand for precision medicine. The market is projected to grow at a 21.81% CAGR through 2031, with contract manufacturing leading at 51.68% market share in 2025. Antisense oligonucleotides dominate at 58.23% revenue, while siRNA is the fastest-growing segment at 23.25% CAGR. Asia-Pacific is the fastest-growing region at 24.56% CAGR, driven by capacity expansion in China, South Korea, and Japan.

The global molecular biology enzymes, reagents and kits market is projected to grow from USD 27.69 billion in 2025 to USD 70.85 billion by 2035, with a CAGR of 9.68%. Growth is driven by increasing adoption of precision medicine, molecular diagnostics, genomics research, and biotechnology R&D. The US market is expected to reach $23.54 billion and Europe $19.32 billion by 2035, with Asia-Pacific showing the fastest growth.

The global Oxidative Stress Assay Market is projected to grow at a CAGR of 9.53% from 2026 to 2035, driven by rising chronic disease prevalence, pharmaceutical R&D investments, and advancements in biomarker diagnostics. North America leads with 38.52% market share, while Asia-Pacific is expected to show the highest growth rate at 10.55%. ELISA technology dominates with 39% market share, and cancer research accounts for 33% of revenue.

The global LIMS market is projected to grow from USD 2.88 billion in 2025 to USD 5.19 billion by 2030, with a CAGR of 12.5%. Growth is driven by increasing demand for laboratory automation, regulatory compliance, cloud-based solutions, and AI integration. North America leads the market, while large enterprises dominate adoption. Key challenges include high maintenance costs and system integration complexities.

The global laboratory equipment services market is projected to grow from USD 28.94 billion in 2025 to USD 62.83 billion by 2035, at a CAGR of 8%. Growth is driven by increased R&D investments in life sciences, stricter regulatory compliance requirements, expansion of biopharma facilities, and adoption of IoT-enhanced predictive maintenance technologies. Repair and maintenance services represent the largest market segment, with North America dominating and Asia Pacific showing the fastest growth.

The global automated liquid handling systems market is valued at USD 2.7 billion in 2025 and is projected to reach USD 6.9 billion by 2035, growing at a CAGR of 9.8%. Growth is driven by increasing pharmaceutical R&D, clinical trials, technological advancements, and demand for automation in diagnostics and molecular testing. Key players include Eppendorf SE, PerkinElmer Inc., Thermo Fisher Scientific Inc., and QIAGEN NV.